Swiss National Bank trimmed its holdings in shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) by 13.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 192,000 shares of the specialty pharmaceutical company’s stock after selling 29,100 shares during the quarter. Swiss National Bank owned 0.32% of Jazz Pharmaceuticals worth $28,990,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. US Bancorp DE raised its position in shares of Jazz Pharmaceuticals by 49.5% during the 4th quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock valued at $147,000 after buying an additional 360 shares in the last quarter. We Are One Seven LLC purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth about $157,000. Brighton Jones LLC purchased a new stake in Jazz Pharmaceuticals in the 1st quarter worth about $205,000. Invictus RG purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth about $206,000. Finally, Macquarie Group Ltd. raised its position in Jazz Pharmaceuticals by 157.1% in the 4th quarter. Macquarie Group Ltd. now owns 1,800 shares of the specialty pharmaceutical company’s stock worth $965,000 after purchasing an additional 1,100 shares during the period. Hedge funds and other institutional investors own 90.62% of the company’s stock.
Get Jazz Pharmaceuticals alerts:NASDAQ JAZZ opened at $167.51 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.88 and a current ratio of 3.00. Jazz Pharmaceuticals has a 52-week low of $128.58 and a 52-week high of $168.48. The company has a market cap of $9.90 billion, a PE ratio of 16.74, a price-to-earnings-growth ratio of 0.85 and a beta of 0.97.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.73 by ($0.15). Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. The business had revenue of $436.40 million for the quarter, compared to the consensus estimate of $440.91 million. equities analysts predict that Jazz Pharmaceuticals will post 11.65 earnings per share for the current year.
In other news, SVP Paul Treacy sold 877 shares of the stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $139.62, for a total transaction of $122,446.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $151.12, for a total transaction of $30,224.00. Following the transaction, the executive vice president now owns 27,681 shares in the company, valued at $4,183,152.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,837 shares of company stock worth $3,200,686. Insiders own 4.30% of the company’s stock.
A number of analysts recently weighed in on JAZZ shares. Seaport Global Securities set a $175.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, April 6th. Piper Jaffray reissued a “buy” rating and issued a $201.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, March 1st. Cantor Fitzgerald reissued a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, April 30th. Bank of America increased their price objective on shares of Jazz Pharmaceuticals from $164.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, February 20th. Finally, B. Riley increased their price objective on shares of Jazz Pharmaceuticals from $206.00 to $211.00 and gave the stock a “buy” rating in a research report on Thursday, May 10th. Seven investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Jazz Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $181.60.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals (NASDAQ:JAZZ).
No comments:
Post a Comment